Skip to main content

IDEAYA Biosciences, Inc. (IDYA) Stock Analysis

Range Bound setup

SellVALUE-TRAP 1/5Moderate Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $28.69: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 8.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Elevated put/call ratio: 3.00; Below-average business quality.

IDEAYA Biosciences is a clinical-stage precision oncology company developing small-molecule targeted therapies and ADCs for molecularly defined solid tumors, organized around synthetic lethality and DNA damage response mechanisms. Revenue is currently nil from product sales; the... Read more

$28.69+67.7% A.UpsideScore 4.8/10#117 of 157 Biotechnology
QualityF-score2 / 9FCF yield-2.30%
Stop $26.83Target $47.48(analyst − 10%)A.R:R 8.3:1
Analyst target$52.75+83.9%16 analysts
$47.48our TP
$28.69price
$52.75mean
$81

Sell if holding. Engine safety override at $28.69: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 8.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Elevated put/call ratio: 3.00; Below-average business quality. Chart setup: RSI 53 mid-range, Bollinger mid-band. Score 4.8/10, moderate confidence.

Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 82d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Val6.5Qual1.5Grw5.0Mom3.6Sent8.1Ins5.8Peer4.2Tech6.5Risk1.84.8OVERALL

Recent Developments — IDEAYA Biosciences, Inc.

Latest news

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
No bull case signals
Risks
Quality below floor (1.5 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)-7.7
Mkt Cap$2.5B
EV/EBITDA-10.2
Profit Mgn-62.2%
ROE-14.3%
Rev Growth—
Beta-0.04
DividendNone
Rating analysts25

Quality Signals

Piotroski F2/9

Options Flow

P/C3.00bearish
IV80%elevated
Max Pain$18-39.0% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Unprofitable operations — net margin -62.2%. Quality floor flags this regardless of sector context.static

Roe
0.0
Roa
0.0
Net Margin
0.0
Fcf Quality
0.0
Piotroski F
2.2
Moat
3.2
Current Ratio
5.0
Cash-burning: FCF -25% of revenueNo competitive moatWeak Piotroski F-Score: 2/9Quality concerns

Risk profile below the gate floor. Component breakdown shows what dragged the score down.static

Put Call
0.0
Implied Vol
0.1
Short Interest
1.9
Debt Equity
1.9
Volatility
2.3
Max Pain Risk
3.0
Days To Cover
3.2
High short interest justified: 16%Elevated put/call: 3.00High IV: 80%Above max pain $18

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Obv
1.0
Ma Position
2.2
Volume
2.7
Rsi
4.5
Macd
7.4
Volume distribution (falling OBV)Below 200-MA but MA still rising (+3.8%/30d) — pullback in uptrend, not confirmed weakness
GatesMomentum 3.6<4.5A.R:R 8.3 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 82d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Aggressive
RSI
53 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MAGOLDEN CROSSSupport $27.66Resistance $32.22

Price Targets

$27
$47
A.Upside+65.5%
A.R:R8.3:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (1.5 < 4.0)
! Momentum score 3.6/10 — below 4.5 minimum

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-08-10 (82d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is IDYA stock a buy right now?

Sell if holding. Engine safety override at $28.69: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 8.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Elevated put/call ratio: 3.00; Below-average business quality. Chart setup: RSI 53 mid-range, Bollinger mid-band. Prior stop was $26.83. Score 4.8/10, moderate confidence.

What is the IDYA stock price target?

Take-profit target: $47.48 (+67.7% upside). Prior stop was $26.83. Stop-loss: $26.83.

What are the risks of investing in IDYA?

Quality below floor (1.5 < 4.0).

Is IDYA overvalued or undervalued?

IDEAYA Biosciences, Inc. trades at a P/E of N/A (forward -7.7). TrendMatrix value score: 6.5/10. Verdict: Sell.

What do analysts say about IDYA?

25 analysts cover IDYA with a consensus score of 4.2/5. Average price target: $53.

What does IDEAYA Biosciences, Inc. do?IDEAYA Biosciences is a clinical-stage precision oncology company developing small-molecule targeted therapies and ADCs...

IDEAYA Biosciences is a clinical-stage precision oncology company developing small-molecule targeted therapies and ADCs for molecularly defined solid tumors, organized around synthetic lethality and DNA damage response mechanisms. Revenue is currently nil from product sales; the company funded primarily through an equity capital base and a $210M upfront from a Servier license for darovasertib outside the US. Nine product candidates are in clinical trials with darovasertib in Phase 2/3 uveal melanoma as the lead.

Related stocks: AUPH (Aurinia Pharmaceuticals Inc) · INCY (Incyte Corporation) · ADMA (ADMA Biologics Inc) · HRMY (Harmony Biosciences Holdings, I) · GLPG (Galapagos NV)